WARNING: SEVERE ALLERGIC REACTIONS

- ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
- Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
- Observe patients in the office for at least 30 minutes following the initial dose.
- Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
- ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
- ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

Criteria for Approval:
- Client must be between 10 and 65 years of age
- Therapy must be initiated 4 months before the expected onset of each grass pollen season.
- Documentation of a grass pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in Oralair: Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens

Chart Note Page #: ____________________________

Re-authorization Criteria
- Initial therapy was approved and initiated 4 months prior to expected onset of grass pollen season.
- Therapy has been continuous throughout grass pollen season.

Initial Authorization: One grass pollen season
Re-authorization: Up to 3 years